{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:31:59Z","timestamp":1770744719979,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.thromres.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T12:34:45Z","timestamp":1654605285000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products"],"prefix":"10.1016","volume":"216","author":[{"given":"J.E.","family":"Meg\u00edas-Vericat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bonanad Boix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1068-7489","authenticated-orcid":false,"given":"R.","family":"Berrueco Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-855X","authenticated-orcid":false,"given":"M.E.","family":"Mingot-Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rodr\u00edguez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Canaro Hirnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mateo Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Calvo Villas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Haya Guaita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mesegu\u00e9 Med\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"L\u00f3pez Jaime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Albo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Palomero-Massanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Vilalta Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Larrod\u00e9","family":"Leci\u00f1ena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.R. Cid","family":"Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Poveda Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.thromres.2022.06.001_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0010","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.001_bb0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 77","key":"10.1016\/j.thromres.2022.06.001_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/ort.1965.36.suppl-77.01","article-title":"Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B","author":"Ahlberg","year":"1965","journal-title":"Acta Orthop Scand"},{"key":"10.1016\/j.thromres.2022.06.001_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years\u2019 experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.thromres.2022.06.001_bb0030","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jth.13867","article-title":"Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia a or B using a population pharmacokinetic approach: communication from the SSC of the ISTH","volume":"15","author":"Iorio","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.001_bb0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.thromres.2019.12.012","article-title":"Extended half-life recombinant products in haemophilia clinical practice - expectations, opportunities and challenges","volume":"196","author":"Chowdary","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2022.06.001_bb0040","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-A critical review of the evidence","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0045","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0036-1571315","article-title":"Prophylaxis for hemophilia in the era of extended half-life factor VIII\/factor IX products","volume":"42","author":"Berntorp","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2022.06.001_bb0050","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII fc fusion protein in hemophilia a patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.06.001_bb0055","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia a","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.06.001_bb0060","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94\u20139027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.001_bb0065","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.001_bb0070","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1111\/hae.13245","article-title":"Association of Hemophilia Centre Directors of Canada (AHCDC). Switching to extended half-life products in Canada - preliminary data","volume":"23","author":"Keepanasseril","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/hae.13758","article-title":"Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia treatment centres for patients with moderate and severe haemophilia","volume":"25","author":"Croteau","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0080","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/hae.13432","article-title":"Clinical use of recombinant factor VIII fc and recombinant factor IX fc in patients with haemophilia A and B","volume":"24","author":"Wang","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/hae.13970","article-title":"The australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors' organisation","volume":"26","author":"Brennan","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0090","first-page":"492","article-title":"A retrospective observational study of rurioctocog alfa pegol in clinical practice in the United States","volume":"26","author":"Aledort","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.thromres.2022.06.001_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hae.13905","article-title":"Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate\/severe haemophilia A: lessons learned with the CHO-KLAT tool","volume":"26","author":"Carcao","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"Collins","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0105","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.001_bb0110","series-title":"myPKFiT for ADVATE user manual","year":"2016"},{"key":"10.1016\/j.thromres.2022.06.001_bb0115","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6558","article-title":"Development of a web-accessible population pharmacokinetic service-hemophilia (WAPPS-Hemo): study protocol","volume":"5","author":"Iorio","year":"2016","journal-title":"JMIR Res. Protoc."},{"key":"10.1016\/j.thromres.2022.06.001_bb0120","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6559","article-title":"Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service - hemophilia (WAPPS-Hemo)","volume":"5","author":"McEneny-King","year":"2016","journal-title":"JMIR Res. Protoc."},{"key":"10.1016\/j.thromres.2022.06.001_bb0125","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Subcommittee on factor VIII, factor IX and rare coagulation disorders of the scientific and standardization Committee of the International Society on thrombosis and hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2022.06.001_bb0130","first-page":"S94","article-title":"Monitoring coagulation factors during surgeryA systematic review","volume":"45","author":"Meg\u00edas-Vericat","year":"2021","journal-title":"Farm Hosp"},{"key":"10.1016\/j.thromres.2022.06.001_bb0135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/hae.13483","article-title":"Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII","volume":"24","author":"Hermans","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/hae.13946","article-title":"Multicentre pharmacokinetic evaluation of rFVIII-fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates","volume":"26","author":"Pouplard","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0145","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/pharmaceutics12040380","article-title":"Real life population pharmacokinetics modelling of eight factors VIII in patients with severe haemophilia A: is it always relevant to switch to an extended half-Life?","volume":"12","author":"Allard","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.thromres.2022.06.001_bb0150","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bjorkman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.06.001_bb0155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/hae.12592","article-title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A","volume":"21","author":"Kepa","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0160","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hae.14078","article-title":"Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia","volume":"26","author":"Turecek","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0165","article-title":"Decreased bleeding rates in patients with hemophilia A switching from standard-half-life FVIII to BAY 94-9027 prophylaxis","author":"Mancuso","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2022.06.001_bb0170","first-page":"39","article-title":"Real-world analysis of dispensed international units of coagulation factor VIII and resultant expenditures for hemophilia a patients: a comparison between standard half-life and extended half-life products","volume":"27","author":"Chhabra","year":"2018","journal-title":"Manag. Care"},{"key":"10.1016\/j.thromres.2022.06.001_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14737167.2020.1789457","article-title":"Cost of patients with hemophilia a treated with standard half-life or extended half-life FVIII in Spain","volume":"21","author":"Kim","year":"2021","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.thromres.2022.06.001_bb0180","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia a: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.06.001_bb0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.13353","article-title":"Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII fc fusion protein","volume":"24","author":"Oldenburg","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0190","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/hae.13803","article-title":"HOw patients view extended half-life products: impressions from real-world experience (The HOPE study)","volume":"25","author":"Khair","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.001_bb0195","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/JBM.S206806","article-title":"Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94\u20139027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia a","volume":"10","author":"Batt","year":"2019","journal-title":"J. Blood Med."},{"key":"10.1016\/j.thromres.2022.06.001_bb0200","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/jth.14469","article-title":"Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia a: is there a difference?","volume":"17","author":"Carcao","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.001_bb0205","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00277-019-03747-2","article-title":"Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia a","volume":"98","author":"Shah","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.thromres.2022.06.001_bb0210","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","article-title":"Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia a","volume":"99","author":"Solms","year":"2020","journal-title":"Ann. Hematol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822002948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822002948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:49:09Z","timestamp":1758736149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822002948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":42,"alternative-id":["S0049384822002948"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.06.001","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}